EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Emerging antioxidant therapies in Friedreich’s ataxia

Fred Jonathan Edzeamey, Zenouska Ramchunder, Charareh Pourzand, Sara Anjomani Virmouni

Frontiers in Pharmacology · 06.02.2024 · 15

DOI: 10.3389/fphar.2024.1359618 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 06.02.2024. Verfasst von Fred Jonathan Edzeamey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ataxia Research Group, Division of Biosciences, Department of Life Sciences, College of Health, Medicine, and Life Sciences (CHMLS), Brunel Universit…. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 164 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Friedreich’s ataxia (FRDA) is a rare childhood neurologic disorder, affecting 1 in 50,000 Caucasians. The disease is caused by the abnormal expansion of the GAA repeat sequence in intron 1 of the FXN gene, leading to the reduced expression of the mitochondrial protein frataxin. The disease is characterised by progressive neurodegeneration, hypertrophic cardiomyopathy, diabetes mellitus and musculoskeletal deformities. The reduced expression of frataxin has been suggested to result in the downregulation of endogenous antioxidant defence mechanisms and mitochondrial bioenergetics, and the increase in mitochondrial iron accumulation thereby leading to oxidative stress. The confirmation of oxidative stress as one of the pathological signatures of FRDA led to the search for antioxidants which can be used as therapeutic modality. Based on this observation, antioxidants with different mechanisms of action have been explored for FRDA therapy since the last two decades. In this review, we bring forth all antioxidants which have been investigated for FRDA therapy and have been signed off for clinical trials. We summarise their various target points in FRDA disease pathway, their performances during clinical trials and possible factors which might have accounted for their failure or otherwise during clinical trials. We also discuss the limitation of the studies completed and propose possible strategies for combinatorial therapy of antioxidants to generate synergistic effect in FRDA patients.

Schlagwörter

Stichwörter der Autor:innen

Friedreich’s ataxiaantioxidantsclinical trialsoxidative stressreactive oxygen species

Autor:innen und Institutionen

  • Ataxia Research Group, Division of Biosciences, Department of Life Sciences, College of Health, Medicine, and Life Sciences (CHMLS), Brunel University London, Uxbridge, United Kingdom.
  • Department of Life Sciences, University of Bath, Bath, United Kingdom.
  • Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom.

Zitieren

APA

Edzeamey, F. J., Ramchunder, Z., Pourzand, C., & Anjomani Virmouni, S. (2024). Emerging antioxidant therapies in Friedreich’s ataxia. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1359618

Vancouver

Edzeamey FJ, Ramchunder Z, Pourzand C, Anjomani Virmouni S. Emerging antioxidant therapies in Friedreich’s ataxia. Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1359618

BibTeX
@article{Edzeamey2024,
  author = {Edzeamey, Fred Jonathan and Ramchunder, Zenouska and Pourzand, Charareh and Anjomani Virmouni, Sara},
  title = {Emerging antioxidant therapies in Friedreich’s ataxia},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1359618}
}
Kostenlos starten →